

ICM6011: Brain and Mind, Disorders of Supraspinal Systems

Academic year 2015-2016

View Online



1.

Sudhof, T. The synaptic vesicle cycle: a cascade of protein-protein interactions. *Nature (London)* (6AD).

2.

The synaptic vesicle cycle: a cascade of protein-protein interactions.

3.

Chen, K. et al. Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures. *Journal of Neuroscience* **27**, 46-58 (2007).

4.

Krisztina, Massa, F., Egertová, M. & Eder, M. The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus.

5.

Nyilas, R., Dudok, B. & Urbán, G. M. Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals.

6.

Solinas, M., Goldberg, S. R. & Piomelli, D. The endocannabinoid system in brain reward

processes. *British Journal of Pharmacology* **154**, 369–383 (2009).

7.

The endocannabinoid system in brain reward processes.

8.

Arendt, T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

9.

Arendt, T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

10.

Dominguez, I. D. & Strooper, B. D. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease.

11.

Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies : Article : *Nature Reviews Neuroscience*.

12.

McMurray, C. T. Huntington's disease: new hope for therapeutics.

13.

De Keyser, J., Sulter, G. & Luiten, P. G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?

14.

Zhu, H. L., Luo, W. Q. & Wang, H. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels.

15.

Fredrik Jarskog, L., Miyamoto, S. & Lieberman, J. A. Schizophrenia: New Pathological Insights and Therapies - Annual Review of Medicine, 58(1):49.

16.

Iritani, S. Neuropathology of schizophrenia: A mini review. Neuropathology **27**, 604–608 (2007).

17.

LARUELLE, M., KEGELES, L. S. & ABI-DARGHAM, A. Glutamate, Dopamine, and Schizophrenia. Annals of the New York Academy of Sciences **1003**, 138–158 (2003).

18.

Torrey, E. F. et al. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychiatry **57**, 252–260 (2005).

19.

Löscher, W. Current status and future directions in the pharmacotherapy of epilepsy.

20.

Mulley, J. C., Scheffer, I. E., Petrou, S. & Berkovic, S. F. Channelopathies as a genetic cause of epilepsy.

21.

Mulley, J. C., Scheffer, I. E., Petrou, S. & Berkovic, S. F. Channelopathies as a genetic cause

of epilepsy.

22.

Maalouf, M., Rho, J. M. & Mattson, M. P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies.

23.

Schmitz, B., Montouris, G., Schäuble, B. & Caleo, S. Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control. *Epilepsia* **51**, 2231-2240 (2010).

24.

Nestler, E. J. Is there a common molecular pathway for addiction? : Article : *Nature Neuroscience*.

25.

Dackis, C. & O'Brien, C. Neurobiology of addiction: treatment and public policy ramifications : Article : *Nature Neuroscience*.

26.

Volkow, N. D., Fowler, J. S. & Wang, G.-J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.